The SMART-NANO project has enabled the development of an innovative and cost-effective technology platform that provides a complete "sample-to-result" solution for the detection, identification and measurement of nanoparticles designed in a wide range of matrices.
The SMART-NANO project has enabled the development of an innovative, cost-effective technology platform that provides a solution "from sample-to-result" for the detection, identification, and measurement of engineered nanoparticles in a wide range of matrices.
UTC-Compiegne, as a Founder Member of the Sorbonne Universities Cluster, has opened its local innovation
ecosystem, its experimental territorial infrastructure, for its partners. We recall that UTC itself benefits from an
experimental university status and is now spreading its academic model outside France as it has already done
in France. The thrust covers two strong concepts, one of which consists of boosting technological research
(with UTT-Troyes) on complex systems already under development in Shanghai. The other concept revolves
round its cursus based on flexible pedagogy which enhances training and aims at closing the gap with the
entrepreneurial world with long placements and workshop projects. This is now being exported to countries
abroad, such as currently to Brazil.
The presentation was delivered by our eyewear expert Candia Tse and cover such important points as:
• Classification of eyewear products for the purposes of compliance
• EU legislations regulating eyewear safety
• What REACH regulations mean for eyewear brands
Nanotechnology is defined as: the application of scientific knowledge to manipulate and control matter at the Nano scale level to make use of size and structure dependent properties and phenomena distinct from those associated with individual atoms or molecules or with bulk materials.
The Nano scale is the size range from approximately 1nm to 100nm.
Nanotechnology exhibits a strong degree of convergence with many other disciplines, such as the information and communications technologies (ICT) industry.
The SMART-NANO project has enabled the development of an innovative, cost-effective technology platform that provides a solution "from sample-to-result" for the detection, identification, and measurement of engineered nanoparticles in a wide range of matrices.
UTC-Compiegne, as a Founder Member of the Sorbonne Universities Cluster, has opened its local innovation
ecosystem, its experimental territorial infrastructure, for its partners. We recall that UTC itself benefits from an
experimental university status and is now spreading its academic model outside France as it has already done
in France. The thrust covers two strong concepts, one of which consists of boosting technological research
(with UTT-Troyes) on complex systems already under development in Shanghai. The other concept revolves
round its cursus based on flexible pedagogy which enhances training and aims at closing the gap with the
entrepreneurial world with long placements and workshop projects. This is now being exported to countries
abroad, such as currently to Brazil.
The presentation was delivered by our eyewear expert Candia Tse and cover such important points as:
• Classification of eyewear products for the purposes of compliance
• EU legislations regulating eyewear safety
• What REACH regulations mean for eyewear brands
Nanotechnology is defined as: the application of scientific knowledge to manipulate and control matter at the Nano scale level to make use of size and structure dependent properties and phenomena distinct from those associated with individual atoms or molecules or with bulk materials.
The Nano scale is the size range from approximately 1nm to 100nm.
Nanotechnology exhibits a strong degree of convergence with many other disciplines, such as the information and communications technologies (ICT) industry.
Nanotechnologies refer to technologies which exploit the unique properties of tiny particles of nanometre size (millionths of a millimetre).
Nanotechnologies represent a fast-growing market; they are already being used in a variety of technologies and consumer products. (Click here for a list of such products)
However, materials containing nanoparticles may be of concern for human health and the environment, and the risks of these recently developed materials need to be assessed.
Are the existing methodologies to assess these risks appropriate?
07b. Nanotechnologies for diagnostics and nanomedicine
Lab on a chip: Miniaturization, Soft lithographies, microfluidics (Navier-Stokes equations, laminar flow in microchannels, main microfluidic components), Selected applications to chemical microreactors, separation systems and Lab On a Chip.
Miniature Drug delivery System uses micro-fabricated devices to administer drugs to the host and has advantages over a conventional drug delivery system
A MEMS based Implantable Drug Delivery System (IDDS) is discussed. The heart of the system is an in-plane MEMS micropumps enables us to make a compact, inexpensive system. A conceptual IDDS design is proposed. This design consists of an implantable unit which houses the micropumps, electronic and power circuitry. This implantable unit is connected to a subcutaneous port via a silicone catheter. The subcutaneous port acts as a refillable reservoir. This leads to a reduction in unit volume and makes the system customizable. The IDDS pumps drug into surrounding tissue with the help of a MEMS based micropumps. Similarly Microneedles are also used in drug administration.
This report gives an overview of patenting activity around Miniature Drug Delivery System. Smart drug delivery system is used for delivering drugs to the host effectively and improves the quality of life of the patients. Patents were categorized as per key Drug Delivery administration methods, types of sensors, applications, communication techniques and analyzed for generating different trends with Patent iNSIGHT Pro.
Miniature Drug Delivery System technology has seen a consistent increase in the number of patent publications from 2008 till 2012 as the need for smart drug delivery has increase globally.
Published: Apr 30, 2013
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
More Related Content
Similar to Newseletter Smartnano 8 - Nanoparticles
Nanotechnologies refer to technologies which exploit the unique properties of tiny particles of nanometre size (millionths of a millimetre).
Nanotechnologies represent a fast-growing market; they are already being used in a variety of technologies and consumer products. (Click here for a list of such products)
However, materials containing nanoparticles may be of concern for human health and the environment, and the risks of these recently developed materials need to be assessed.
Are the existing methodologies to assess these risks appropriate?
07b. Nanotechnologies for diagnostics and nanomedicine
Lab on a chip: Miniaturization, Soft lithographies, microfluidics (Navier-Stokes equations, laminar flow in microchannels, main microfluidic components), Selected applications to chemical microreactors, separation systems and Lab On a Chip.
Miniature Drug delivery System uses micro-fabricated devices to administer drugs to the host and has advantages over a conventional drug delivery system
A MEMS based Implantable Drug Delivery System (IDDS) is discussed. The heart of the system is an in-plane MEMS micropumps enables us to make a compact, inexpensive system. A conceptual IDDS design is proposed. This design consists of an implantable unit which houses the micropumps, electronic and power circuitry. This implantable unit is connected to a subcutaneous port via a silicone catheter. The subcutaneous port acts as a refillable reservoir. This leads to a reduction in unit volume and makes the system customizable. The IDDS pumps drug into surrounding tissue with the help of a MEMS based micropumps. Similarly Microneedles are also used in drug administration.
This report gives an overview of patenting activity around Miniature Drug Delivery System. Smart drug delivery system is used for delivering drugs to the host effectively and improves the quality of life of the patients. Patents were categorized as per key Drug Delivery administration methods, types of sensors, applications, communication techniques and analyzed for generating different trends with Patent iNSIGHT Pro.
Miniature Drug Delivery System technology has seen a consistent increase in the number of patent publications from 2008 till 2012 as the need for smart drug delivery has increase globally.
Published: Apr 30, 2013
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...
Newseletter Smartnano 8 - Nanoparticles
1. N E W S L E T T E R Programme: FP7 NMP 2011.1.3-1
Contact n° 280779
Could you give us a
brief overview of your
scientific services and their
applications?
CSEM is a private Swiss Research and
Technology Organization (RTO), with
the mission to develop microtechnologies
and transfer them to the industrial sector
(in Switzerland, as a priority, but not
only) in order to reinforce its competitive
advantage. This transfer takes place via
of cooperation agreements with existing
companies or, in some cases, via the
creation of start-ups: More than 40
startups were created at CSEM since its
founding, some of which are now global
leaders in there sectors (e.g. Heptagon).
In what particularly do you
feel innovative?
CSEM offers the whole chain from
technology scouting, feasibility studies,
simulations, prototyping, testing, up
to small series production in special
cases. CSEM can count on more than
400 highly qualified people with very
different technology background, from
physics, to engineering and biology.
This multidisciplinarity, and the
amount of know-how available in
house, are quite unique, and allow us
to accelerate the development times by
offering ‘one-stop-shop’ solutions to our
customers.
What kind of R&D
technology programs are
you developing?
CSEM own R&D programs are
divided in the following areas: MEMS,
Surface Engineering, Systems,
Ultra-low-power integrated systems,
photovoltaic and energy management.
Our collaborations with industrial
customers and other academic partners,
allows us to explore other application
area, for example through EU-funded
projects.
S m a r t N a n o 1
SmartNano project -newsletter n° 8
only for project dissemination activities
Dr. Stefano
Cattaneo
Project Manager,
CSEM and Project
Coordinator,
SMARTNANO
Nanoparticles in cosmetics:
latest news about regulations
The Scientific Committee on Consumer Safety (SCCS) recently discussed and approved new as-
sessments about some ingredients used in their nano form in cosmetic products.
In particular, new rules were established on the use of insoluble nanoparticles as UV-
filters in sunscreens, such as zinc oxide and Tinosorb M, in order to make products safer
for the consumer and cleaner for the environment.
Here the latest news about regulations are reported.
Zinc oxide
The use of zinc oxide (ZnO) in the form of nano-sized pigment has been debated much
in these last years. In particular, there has been concern that ZnO nanoparticles might
be absorbed into the skin and have toxic consequences in humans, especially with a
long-term use.
About CSEM -
Micro-and
nanotechnology at
CSEM
CSEM, The Swiss Center for Elec-
tronics and Microtechnology, is a
private, non-profit Swiss research
and technology organization focused
on generating value for a sustainable
world.
Since its creation in 1984, CSEM
has focused on bringing innovation
to industry in the field of micro- and
nanotechnologies by developing inno-
vative technologies, integrating them
into working solutions and converting
them into commercial success stories.
The potential of such innovations
can only be realized if the design is
optimized at the product level rather
than at the component level, and
if technologies are compatible with
Follows at pag. 2 >
large-scale manufacturing processes.
CSEM’s core competencies in micro-
technology and electronics as well as
mass-manufacturing methods place
the center in a unique position to pro-
vide integrated solutions addressing
the markets of life sciences, clinical di-
agnostics, and tox/pharma as well as
food and environmental monitoring.
Modern applications require com-
ponents with optimized surfaces.
The optical, chemical, and biological
properties of a surface are to a large
extent determined by its nanometer-
scale characteristics. CSEM develops
techniques to generate micro- and
nanoscale structures with a high level
of precision and reliability, and with a
chemical composition of choice.
In addition to the many technologies
available in house, CSEM is proud
to be able to count on collaborations
with leading research institutes and
companies in Switzerland and abroad.
Thanks to this network, and to ex-
citing collaborative project such as
SMART-NANO, CSEM is confident
that its micro- and nanotechnologies
will continue to lead to solutions with
increased functionality at lower cost.
2. S m a r t N a n o 2
N E W S L E T T E R
What was the driving force
that brought CSEM into
SMARTNANO?
Over the past years, CSEM developed
a range of technologies with potential
applications in nanoparticle analysis.
This was however not a current
application at CSEM. Through
a previous project in water quality
analysis, we were introduced to the
Joint Research Institute in Ispra
and other companies and institutes
working in nanoparticle detection. Very
quickly we realized the potential for a
collaboration and decided to submit a
joint proposal. The collaboration has
been extremely fruitful and enriching
and we are hoping that this will
continue in future H2020 projects.
Benchmarking the SMARTNANO platform
The Smartnano platform was bench-
marked on four models for possible ap-
plications: cosmetics, food, environmen-
tal samples and in biota samples.
The cosmetic sample, TiO2
nanoparti-
cles in a sunscreen matrix, showed clear
results, comparable to the ones achiev-
able with high-end commercial devices.
The food sample, SiO2
nanoparticles in
low fat milk, also confirmed the validity
of the platform and its accuracy.
The environmental sample (silver nano-
particles in seawater samples) confirmed
that the performance of the upgraded
flow field-flow fractionation core and de-
tectors is excellent for the size separation
and characterization of nanoparticles at
sub-μg ml-1 concentrations over a wide
range of nanoparticles sizes. Nanoparti-
cles in biota (silver nanoparticles inside
bacteria and protozoa) provided further
confirmations.
Overall, the Smartnano platform
proved to be able to separate and char-
acterize ENPs in a wide range of com-
plex matrices with the same accuracy
and sensitivity of currently available
commercial devices, despite using much
Continues from pag. 2 Several in vitro and in vivo studies using both animal and human skin have shown that
these NPs do not penetrate the underlying layers of skin, suggesting that systemic ab-
sorption of zinc oxide in this form is unlikely, as confirmed by the last opinion of SCCS
in its comprehensive review of ZnO NPs toxicological profile.
The Committee concluded that the use of these nanoparticles “can be considered not to pose
a risk of adverse effects in humans after dermal application” if used as a UV filter in sunscreens
at a concentration of up to 25%, with the exception of applications that might lead to
inhalation exposure, such as sprayable products.
Tinosorb M
In this case the Scientific Committee on Consumer Safety declared it cannot assess the safety of
this chemical in its nano form yet, as no genotoxicity data are available. And no more
animal testing for these kind of products is allowed since 2013.
Furthermore, in its last opinion SCCS also highlighted the potential risk of accumula-
tion of these nanoparticles in the environment due to its poor biodegradability.
For all these reasons, the use of Tinosorb M as UV-filter in its nano form has been cur-
rently banned in Europe.
smaller volumes of solvents and eluents,
and with shorter run times and easier
maintenance. With all the four models,
the platform achieved good results in
terms of accuracy, sensitivity, selectivity,
recovery limit of detection and limit of
quantification. Ultimately, this platform
validation work represents a stepping
stone on the development path towards
increased instrumental sensitivity for the
physical characterization of nanoparti-
cles in complex matrices.
3. S m a r t N a n o 3
N E W S L E T T E R
“Closer to the Market”
Roadmap (CTTM) now finalised
The NanoSafety Cluster’s “Closer to the Market” Roadmap (CTTM) is a multi-dimen-
sional, stepwise plan targeting a framework to deliver safe nano-enabled products to the
market.
After some years of discussions and consultations with a huge number of experts in the
nanosafety-field, conferences at which the issue of market implementation of nanotech-
nologies was talked about, writing hours/days, and finally two public consultation rounds,
the CTTM is now finalized.
As stated in the Executive Summary: “Nano-products and nano-enabled applications
need a clear and easy-to-follow human and environmental safety framework for the devel-
opment along the innovation chain from initial idea to market and beyond that facilitates
navigation through the complex regulatory and approval processes under which different
product categories fall.
The missing framework results in a lack of:
(i) solid data regarding roadblocks to market penetration of nano-enabled products as
well as the absence of
(ii) transparency in terms of which products (e.g. containing nanomaterials (NMs); nano-
enabled products) are on the market (e.g. registries) and voluntary schemes and label-
ling requirements for cosmetics and food, which processes are used for manufacturing
nano-enabled products, and
(iii) meager inclusiveness in the dialogue (between all stakeholders) most likely exist as a
result of the missing framework.
The Closer-to-the-Market-Roadmap (CTTM) aims at speeding up the progress towards
market implementation of nanotechnologies by outlining the steps needed to develop
such a framework. In its current form it is addressed towards policy makers, but the ulti-
mate framework will be designed for use by SME and enterprise organisations”.
Download it at http://www.nanosafetycluster.eu, and get involved in its implementation
through the Cluster!
(from: Nanosafety Cluster Newsletter N° 7 - Lesley Tobin)
SMARTNANO
project exploitation:
what now?
The Smartnano Platform is complete.
The prototype device was extensively
tested, and provides a completely new
approach to nano-measurements in
complex matrix: for the first time, sever-
al detection and measurement methods
are combined and integrated in a unique
testing platform.
Now that the project is complete, the
Smartnano consortium is moving to
exploit its results in several ways. The
research performed on the platform will
be the basis of new AF4 systems designed
to be both economical and more ecologi-
cally compatible.
The experience achieved in measuring,
identifying and characterizing the size
distribution of engineered nanoparticles
in complex matrices will be the starting
point for new testing services.
The availability of a cheaper, easier sys-
tem to characterize nanoparticles direct-
ly in complex matrices will likely impact
the manufacturing of nano-sized prod-
ucts as well.
The Smartnano consortium will moni-
tor the development of these aspects over
the next years. New devices and services
will be announced on the websites of in-
volved partners as well.
4. S m a r t N a n o 4
N E W S L E T T E R
NanoSafety Cluster Meeting
14 September 2016
Stockholm, Sweden
2nd
NanoSafety Forum for Young
Scientist
15-16th
September 2016
Visby, Gotland, Sweden
Agenda ClosureNext events
Special thanks:
The Smartnano team would like to thank all partners involved in the four years
of the project.
Our special thanks to:
Dr. Stephanne Follonier
former coordinator of the SMARTNANO project.
Dr. Nicolas Segebarth
Project Officer
Dr. Daniel Breitenstein
Project Technical Advisor of the European Commission - FP7.
The International Advisory Board:
Dr. Thomas Koch
Head of Division, Analytical Intelligence, Kronos International, Inc.
Dr. Paul Reip,
Director, Government and Strategic Programmes, Intrinsiq Materials Ltd
Our sincere thanks to all the people that followed us over the past four years,
by connecting with our social networks, registering to the newsletter, attending
conferences or joining us during the Paris 2016 InCosmetics event in April.
We are grateful for your interest.
For any inquiries, please feel free to contact us at info@smartnano.org
or visit our official website: www.smartnano.org.
Follow us on linkedin
To receive the next number of this
newsletter register you profile on http://www.smartnano.org/signin-newsletter.aspx
SMARTNANO Project